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thrombosis rates to decrease a syndrome, which affects
only 1–8% of the accesses, seems to have an unfavorable
risk benefit profile.
The MILLER measured, standardized banding proce-
dure is successful because it allows for precise application
of resistance into a system.2 This procedure is minimally
invasive and can be performed multiple times just as easily
as it can be undone by simply dilating the band with an
angioplasty balloon. Ligation of the perforating vein
definitely seems to be a good idea in helping the superficial
veins to mature. However, it is unlikely to achieve a high
level of success in the treatment and prevention of DASS.
Although it is a feasible treatment, limited precision of
flow volume reduction and irreversibility lead to the same
problems that made traditional banding procedures
unsuccessful.
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To the Editor: Cotter et al.1 used United States Renal Data
System data from 14,001 incident patients to estimate the
dose–response relationship between epoetin (EPO) and
hematocrit. The authors used their analysis to infer the
maximum effective EPO dose and suggested that this should
inform Federal reimbursement policy. However, the analytic
approach used is inconsistent with FDA guidance and the
inferred maximum dose is not likely to be generalizable to the
US dialysis population. We think it is inadvisable to support
reimbursement policies based on inferential information
without careful consideration of the potential clinical
consequences.
When there is a time delay in clinical response (for
example, hemoglobin) following dosing, FDA recommends
parallel dose–response studies where patients receive constant
doses over fixed time periods with no target ceiling, such as
that proposed by Eschbach et al.2 However, Cotter et al.3 used
observational data containing frequent EPO dose titrations,
analyzed with marginal structural modeling. In studies of
flexible dosing, FDA recommends employing mixed-effects
regression, which accounts for interpatient variability in EPO
responsiveness. This is important because a broad range of
EPO doses (B40-fold) are required to achieve target
hemoglobin levels in individuals.4 The application of
unconventional analytics using observational data should
not supplant knowledge gained by the established approach
of controlled clinical trials designed to estimate dose–re-
sponse. Inferring a maximum effective dose from an
estimated mean might result in inadequate dosing for many
patients. Any new EPO policy should be based on the most
rigorous data and analyses, with careful assessment of the
potential impact.
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Critchlow et al.1 state that ‘the application of unconven-
tional analytics using observational data should not
supplant knowledge gained via the established approach
of controlled clinical trials designed to estimate dose–
response.’ We agree. However, controlled trials might
not provide a generalizable dose–response curve if more
sick patients who require higher doses of erythropoiesis
stimulating agents are under-represented because of
restricted enrollment criteria, patient’s underlying disease
burden, etc. Therefore, controlled trials based on such
restrictions are likely to underestimate the range of
erythropoiesis stimulating agent dose required in the
general hemodialysis population.
In contrast, our analysis of dose–response uses data
from an unselected medicare population and over the dose
range currently used by clinicians. We would encourage
Amgen and others to attempt to resolve the dose–response
issue with appropriately designed clinical trials in a
heterogeneous population. In the absence of such trials,
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